Received Jun 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
she was diagnosed with cancer after receiving the first Shingrix vaccine; This serious case was reported by a consumer via call center representative and described the occurrence of cancer in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included hypertension. Concomitant products included lisinopril and amlodipine. In FEB-2025, the patient received the 1st dose of Shingrix. In FEB-2025, less than a month after receiving Shingrix, the patient experienced cancer (Verbatim: she was diagnosed with cancer after receiving the first Shingrix vaccine) (serious criteria GSK medically significant). The outcome of the cancer was unknown. It was unknown if the reporter considered the cancer to be related to Shingrix. The company considered the cancer to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 18-JUN-2025 Customer reported that she was diagnosed with cancer after receiving first dose of Shingrix vaccine.; Sender's Comments: Neoplasm malignant is an unlisted event which is considered unrelated to GSK vaccine Shingrix.
Hypertension
LISINOPRIL; AMLODIPINE